HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of extracorporeal membrane oxygenation on survival of infants with congenital diaphragmatic hernia.

Abstract
To determine the effect of extracorporeal membrane oxygenation (ECMO) on the survival of infants with congenital diaphragmatic hernia, we undertook a retrospective review of 31 infants with congenital diaphragmatic hernia treated at Children's National Medical Center. Infants were categorized by means of the Bohn quadrant analysis to determine the impact of ECMO on infants with congenital diaphragmatic hernia and a "poor prognosis." All infants assigned to the Bohn 100% mortality quadrant required ECMO. The survival rate in this group was 86% (6/7) when assessed preoperatively and 67% (6/9) when assessed postoperatively. Comparison of the change occurring in ventilation index and arterial carbon dioxide pressure demonstrated that after repair the clinical condition of 48% of infants deteriorated, 40% improved, and 12% remained unchanged. Of the 12 infants whose condition was worse after surgery, 11 eventually required ECMO. Our review demonstrates that ECMO improved survival significantly in infants with congenital diaphragmatic hernia who had a "poor prognosis" by the criteria of Bohn et al. We recommend consideration of ECMO for all infants with congenital diaphragmatic hernia for whom maximal medical therapy has failed.
AuthorsK P Van Meurs, K D Newman, K D Anderson, B L Short
JournalThe Journal of pediatrics (J Pediatr) Vol. 117 Issue 6 Pg. 954-60 (Dec 1990) ISSN: 0022-3476 [Print] United States
PMID2246699 (Publication Type: Journal Article)
Topics
  • Evaluation Studies as Topic
  • Extracorporeal Membrane Oxygenation (standards)
  • Female
  • Hernia, Diaphragmatic (complications, surgery)
  • Hernias, Diaphragmatic, Congenital
  • Humans
  • Infant, Newborn
  • Male
  • Postoperative Complications (etiology, mortality, therapy)
  • Prognosis
  • Respiratory Function Tests
  • Respiratory Insufficiency (etiology, mortality, therapy)
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: